Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

2004 ambien buy daily feb statistics About Migraine Migraine headaches affect an estimated 30 million people in the United States and disproportionately affect women 3 to 1. Kowa's pharmaceutical division is focused on cardiovascular therapeutics, with fiscal year 2008 sales of the company's flagship product, LIVALOŽ (pitavastatin) totaling . APR has signed licensing agreements with pharmaceutical companies in 117 countries worldwide and its sales are almost totally achieved abroad.ch., July 2 /PRNewswire-FirstCall/ -- Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of Aversion(R) (abuse deterrent) Technology product candidates and other innovative abuse deterrent technologies.S.

.


NewsA Level

In randomized clinical trials, Cambia was shown to be effective not only in migraine pain, but also in treating photophobia (sensitivity to light), phonophobia (sensitivity to sound), and nausea commonly associated with migraine attacks. "The approval is the culmination of over three years of effort from our partners at Applied Pharma Research and the internal team at Kowa," said William Maichle, Chief Operating Officer of Kowa Pharmaceuticals America, Inc. "Patients and physicians consistently mention rapid pain relief as most important when asked about primary attributes of a migraine medication. and Kowa Pharmaceuticals America, Inc. R&D activities are carried out directly or under contract. Acurox utilizes Acura's proprietary Aversion Technology, which is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of dissolved tablets and nasal snorting of crushed tablets. Acura Pharmaceuticals, Inc..